Ella Morishita

Head of Small Molecule Drug Discovery at Veritas In Silico Inc.

Presenter

Veritas In Silico aims to build a society where every patient can look forward to a brighter future through next-generation medicines targeting the messenger RNA (mRNA). With our proprietary ibVIS platform, we are uncovering new therapeutic targets on mRNAs and discovering molecules that bind to and modulate the function of the mRNA, thereby impacting disease. The discovery of mRNA-targeted medicines is a promising direction for drug development and a new paradigm for the pharmaceutical industry. It has the potential for application to any disease, including those for which conventional protein-targeted discovery has not yielded effective treatments. Currently, we are discovering mRNA-targeted medicines through multiple partnerships with leading global and Japanese companies, such as Takeda, Shionogi, Toray, and RaQualia. We have drug discovery programs in neurological disorders, cancer, infection, and rare diseases. Founded in 2016, Veritas In Silico is a publicly-listed biotech company based in Tokyo, Kanagawa, and Niigata, Japan. Our team of pathfinders has expertise in a wide range of fields including those necessary for traditional drug discovery, as well as RNA biology, informatics, and artificial intelligence. With an experienced management team at the helm and alongside our current and future partners, we are well-positioned to revolutionize drug discovery and deliver more effective and safe treatments to patients worldwide.